Martin Ridderstråle

Martin Ridderstråle is the SVP, Medical Science & Chief Medical Officer at Novo Nordisk Foundation. Martin has been with Novo Nordisk since September 2018 and in their current role since October 2020. Prior to that, they served as the Corporate Vice President, Clinical Pharmacology & Translational Medicine at Novo Nordisk from March 2016 to August 2018. Before joining Novo Nordisk, Ridderstråle was the Vice President and Head of Clinic at Steno Diabetes Center from March 2013 to February 2016.

Ridderstråle has also served as the Chairman of the Board for Network against obesity in Skåne (NOBiS) from January 2009 to February 2013 and the Chairman of the board for Regional Medical Council for Diabetes and Endocrinology from January 2009 to December 2012. Martin was also the Head of Medical Advisory Board for Rashid Centre for Diabetes and Research from January 2009 to February 2013 and Deputy Head of Division for Skåne University Hospital from January 2010 to December 2012.

Martin Ridderstråle has an MBA from Copenhagen Business School, a PhD in molecular signalling from Lund University Medical Faculty, and an MD from Lund University Medical Faculty. Martin also has a PhD in diabetes from Harvard Medical School.

They are on a team with Hanna Line Jakobsen - SVP, Social & Humanitarian, Niels-Henrik von Holstein-Rathlou - SVP, Biomedicine & Health Sciences, and Petrina Knowles Gjelstrup - SVP, People & Organisation. Martin Ridderstråle reports to Mads Krogsgaard Thomsen, CEO.